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ABSTRACT
Background Irritable bowel syndrome with diarrhoea
(IBS-D) is particularly debilitating due to urgency and
episodic incontinence. Some 5-hydroxytryptamine 3
(5-HT3) receptor antagonists (5-HT3RAs) have proven
effective but have serious side effects. Ondansetron, also
a 5-HT3RA, has been widely used as an antiemetic with
an excellent safety record for over two decades. Our aim
was to assess its effectiveness in IBS-D.
Methods 120 patients meeting Rome III criteria for
IBS-D entered a randomised, double-blind, placebo-
controlled crossover study of 5 weeks of ondansetron
4 mg versus placebo with dose titration allowed, up to
two tablets three times daily in the ﬁrst 3 weeks.
Patients completed daily diaries documenting stool
consistency using the Bristol Stool Form score. Gut
transit was measured in the last week of each treatment.
The primary endpoint was average stool consistency in
the last 2 weeks of treatment.
Results Ondansetron signiﬁcantly improved stool
consistency (mean difference in stool form between
ondansetron and placebo −0.9, 95% CI −1.1 to −0.6,
p<0.001). Compared with placebo, patients on
ondansetron experienced fewer days with urgency
(p<0.001), lower urgency scores (p<0.001), reduced
frequency of defaecation (p=0.002) and less bloating
(p=0.002), although pain scores did not change
signiﬁcantly. IBS symptom severity score fell more with
ondansetron than placebo (83±9.8 vs 37±9.7,
p=0.001). 65% reported adequate relief with
ondansetron but not placebo compared with 14%
reporting relief with placebo but not ondansetron,
relative risk 4.7, 95% CI 2.6 to 8.5, p<0.001.
Conclusions Ondansetron relieves some of the most
intrusive symptoms of IBS-D, namely loose stools,
frequency and urgency.
INTRODUCTION, BACKGROUND AND
OBJECTIVES
Irritable bowel syndrome with diarrhoea (IBS-D)
affects approximately 3% of the general population
and accounts for approximately 20% of gastro-
enterology outpatient visits in the UK. Since many
conditions can cause diarrhoea, such patients typic-
ally undergo numerous negative tests. IBS regard-
less of subtype is also associated with considerable
impairment of quality of life.1 2 IBS-D is particu-
larly a debilitating form of IBS as it reduces the
ability to eat out and socialise because of fear of
pain, urgent defaecation and even incontinence.
Serotonin (5-hydroxytryptamine (5-HT)) is a major
mediator in the gut, signalling via afferent nerves to
inﬂuence gut motility and secretion.3 5-HT3 recep-
tor antagonists (5HT3RAs) block the vagal stimula-
tion induced by 5-HT4 and were developed as a
highly effective treatment for chemotherapy-
induced nausea and vomiting, known to be
mediated via vagal stimulation by cisplatinum-
induced 5-HT release.5 It was soon discovered that
5HT3RAs also cause constipation.6 Early studies
with ondansetron demonstrated that 16 mg three
times a day, the usual dose for chemotherapy-
induced emesis, delayed colonic transit in healthy
subjects,7 and reduced the postprandial increase in
colonic tone in carcinoid diarrhoea.8 A small trial
using the much lower dose of 4 mg three times a
day suggested beneﬁt in IBS and functional dyspep-
sia.9 Our aim was to determine whether this inex-
pensive, safe generic drug would provide similar
relief to patients with IBS-D. We also wished to
Signiﬁcance of this study
What is already known about this subject?
▸ 5-Hydroxytryptamine 3 receptor antagonists
(5-HT3RAs) improve symptoms of irritable
bowel syndrome with diarrhoea (IBS-D).
▸ Alosetron, the best studied 5-HT3RA, was
withdrawn from general use because of
constipation and rarely ischaemic colitis.
▸ Ondansetron is a 5-HT3RA widely used as an
anti-nauseant for over 20 years and never
associated with ischaemic colitis.
What are the new ﬁndings?
▸ Ondansetron improves symptoms of frequent
loose stools with urgency characteristic of
IBS-D.
▸ Ondansetron slows the accelerated colonic
transit associated with IBS-D.
▸ Those with severe diarrhoea respond less well.
How might it impact on clinical practice in
the foreseeable future
▸ Ondansetron is a safe inexpensive 5-HT3RA
available worldwide which could improve
symptoms in many patients with IBS-D with
mild to moderate symptoms.
▸ The main beneﬁt, which is seen within 7 days,
is to reduce urgency.
▸ The median dose is 4 mg per day in those who
respond.
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determine the mechanism of action and in particular whether
clinical factors or polymorphisms in the SERT genotype could
predict those that would respond, as has been suggested for
alosetron.10
METHODS
Trial design
This was a two-centre, randomised, double-blind, placebo-
controlled crossover study of ondansetron 4 mg/tablet versus
placebo. Patients were given one to two tablets three times a day
with dose titration for the ﬁrst 3 weeks of each period and a 2–
3-week washout period (ﬁgure 1). The trial was registered on
clinicaltrials.gov (identiﬁer NCT00745004), approved by
Nottingham Research Ethics Committee 2 (REC reference
number 08/H0408/134) and by the Medicines and Healthcare
Regulatory authority (MHRA, London, UK), and conducted
according to Good Clinical Practice guidelines. Funding was
provided by the National Institute for Health Research through
a Research for Patient Beneﬁt grant and salary support for Dr
Garsed from the Nottingham Digestive Diseases Biomedical
Research Unit. There were no changes to protocol from that ini-
tially registered with clinicaltrials.gov.
Randomisation
Sequence allocation randomisation was carried out by
Nottingham Clinical Trials Support Unit (CTSU) with random
permuted blocks of randomly varying size and stratiﬁed by
centre. The supervising staff obtained a randomisation reference
number by a remote, internet-based randomisation system. All
participants stayed blinded until the study, data collection and
assessments were complete. CTSU Data Manager and the
Queen Medical Centre (QMC) Trials pharmacy had access to
the treatment allocations. The code was never broken.
Sample size calculation
From previous studies11 the estimated mean (SD) stool consist-
ency in healthy controls was 3.6 (1.1) and recent unpublished
data suggest a within-person correlation of 0.5. To detect a dif-
ference of 0.4 which was considered clinically signﬁcant with
90% power and 1% type I error we needed 113 subjects. To
acount for dropouts we randomised 120.
Participants
Patients with IBS-D were recruited from IBS clinics at the
Queen’s Medical Centre Nottingham and Wythenshawe
Hospital, Manchester and via the Trent Primary Care Research
Network from 1 January 2009 to May 2011 using the Rome III
diagnostic criteria.12 To exclude other causes of diarrhoea we
required a normal colonoscopy and colonic biopsies, normal full
blood count, serum calcium and albumen, C-reactive protein and
negative serological tests for celiac disease. All patients consum-
ing more than the equivalent of 240 ml of milk/day were tested
for lactose intolerance. Most had either a therapeutic trial of
colestyramine or a test of bile salt absorption using the 7-day
retention of selenium75-labelled homocholic acid taurine to
exclude bile salt malabsorption. Patients gave written informed
consent. Inclusion criteria were age 18–75 years; meeting Rome
III criteria; no evidence of inﬂammatory bowel disease/micro-
scopic colitis and able to give informed consent. Women of child-
bearing potential tested negatively on pregnancy test and had to
agree to adequate contraception during the study. Patients on
selective serotonin reuptake inhibitors or tricyclic antidepressants
were included, provided they had been on medication for at least
3 months and the dose remained unaltered throughout the study.
Exclusion criteria were pregnancy or breast feeding, unwilling to
stop anti-diarrhoeal medication (loperamide or codeine phos-
phate), prior abdominal surgery other than appendectomy and
cholecystectomy, being in another trial or being in the opinion of
the investigator unsuitable.
Healthy controls for transit studies
We also studied 21 healthy controls to provide normal values
for the transit studies. They completed the same questionnaires
and underwent the same transit measurement protocol. None
Figure 1 Study design. This shows the two 5-week treatment periods during which subjects were randomised to either ondansetron or placebo.
Week 1 was for baseline assessment, Each 5-week treatment period allowed dose adjustment until weeks 4 and 5 when no further dose adjustment
or rescue medication was allowed. Symptoms on weeks 4 and 5 provided the clinical endpoints. Symptoms were assessed throughout the study and
during the washout period to ensure symptoms had returned to baseline before starting the next treatment. Frequent visits and telephone contact
ensured protocol compliance.
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met Rome III IBS criteria. They comprised 16 women and 5
men, with median age (IQR) of 45 (23–56) years. Bowel fre-
quency was median (IQR) of 1.0 (1.0–1.4) bowel movements
per day.
Intervention
Each participant received 5 weeks of oral placebo treatment and
5 weeks of ondansetron 4 mg tablets using dose titration for the
ﬁrst 3 weeks of each period with a 2–3-week washout period in
between each treatment period (ﬁgure 1). The hospital phar-
macy provided the 5-week drug supply at the beginning of each
period. The investigational medicinal product was either a 4 mg
ondansetron tablet (Pliva, Zagreb, Croatia) or placebo, both
identically over-encapsulated in a gelatine capsule by Bilcare
(Crickhowell, Powys, UK). The placebo formulation matched
that of the ondansetron in appearance and composition, except
for the active drug.
The patients were instructed to start with one capsule once a
day, increasing daily to a maximum of two capsules three times
a day, depending on the response. If stool consistency increased
to stool form 1 or 2, or if bowel frequency dropped below one
per day the dose was reduced to a minimum of one capsule
taken every 2 days. Patients were required to stay on a stable
dose for the last 2 weeks of each period. Loperamide, 2 mg
twice daily, was allowed as rescue medication in the event of
uncontrolled diarrhoea, but needed to be discontinued for the
ﬁnal 2 weeks of each period. Patients attended for a total of
seven visits as follows (ﬁgure 1): screening visit 1 was followed
by a 1-week period when stool and symptom diaries were com-
pleted (week 1). At visit 2, after checking patients met Rome III
criteria and had completed the stool diaries, they were enrolled
and instructed to start treatment at one capsule daily increasing
or decreasing the dose by one capsule per day every 2 days to a
maximum of two capsules three times daily. They were told to
increase the dose if the stool form was 6 or 7 and decrease if it
was 2 or 1. After 1 week patients were telephoned to conﬁrm
the dose was optimum. They were also called a few days before
visit 3 to conﬁrm the appointment and before visit 4 to remind
them to take the transit markers for 3 days before the visit. Visit
3 was after 3 weeks of treatment and visit 4 was the ﬁnal visit of
the ﬁrst treatment period when stool diaries were collected and
colonic transit assessed by a plain X-ray. There was then a
2-week washout which was extended if necessary to ensure
bowel habit had returned to baseline. Return to baseline was
conﬁrmed by asking patients whether their bowel dysfunction
was back to pre-study levels and this was objectively corrobo-
rated by examination of the visit 5 diaries. In those participants
in whom pre-study levels had not been reached by 2 weeks, ini-
tiation of the second treatment phase was delayed until pre-
study levels were conﬁrmed.
The second treatment period was identical to the ﬁrst.
Compliance was monitored by asking the patient at each study
visit and by a ﬁnal pill count of all returned medicines.
Data collection
Personal baseline data were collected at visit 1: age, gender,
depression and anxiety scores from the Hospital and Depression
Scale, score from the Patient Health Questionnaire 15,13 per-
ceived stress score from the Perceived Stress Scale
Questionnaire.14 IBS-related quality of life from the IBS Quality
of Life Questionnaire15 and IBS severity score from the IBSS
Severity Score Questionnaire16 were collected at visit 1 and at
the end of each treatment period (visits 4 and 7). We used our
previously described daily stool diary11 throughout the study to
provide information on stool form (Bristol Stool Form score,17
from 1 (very hard) to 7 (water)) and pain perception, urgency
of defecation and bloating, the last three scored as none, mild,
moderate or severe (0–3). Frequency of defaecation and number
of days when pain, urgency or bloating was present were
recorded.
The baseline values are averages from the screening week.
Endpoints
The primary endpoint (stool form) and secondary endpoints
(pain perception, urgency of defaecation, bloating, frequency of
defaecation per day, number of days per week with pain,
urgency or bloating, and IBS SS) are averages over the last
2 weeks of each treatment period. Information provided for less
than 10 days (out of 14) was recorded as missing.
At the end of each period patients were asked: ‘over the last
2 weeks did you obtain adequate relief of your IBS symptoms?’,
and at the end of the study: ‘which treatment if any did you
prefer?’, and ‘which treatment, if any would you prefer to con-
tinue with now the trial has ﬁnished?’ Percentage reporting
adequate relief of IBS symtpoms (yes/no), proportion of patients
preferring particular treatment (yes/no) and proportion wanting
to continue with particular treatment (yes/no) were recorded as
secondary endpoints.
Bloods were collected for genetic analysis for the serotonin
transporter promoter polymorphism (see online supplementary
appendix for methods and results).
Responder deﬁnition
We used the US Food and Drug Administration (FDA) deﬁnition
of ‘a Stool Consistency Responder’ as a ‘patient who experi-
ences a 50 percent or greater reduction in the number of days
per week with at least one stool that has a consistency of Type 6
or 7 compared with baseline’ and a ‘pain responder’ as a patient
who experienced a fall of 30% in pain compared to baseline.18
The FDA recommends that for IBS a dual endpoint should be
used to deﬁne a ‘responder’ who should be both a Stool
Consistency responder and a ‘pain responder’.
Whole gut transit measurement
We used the Metcalf ’s radio-opaque marker technique.19
Subjects took 20 silicon markers impregnated with 13.5%
barium (Altimex, Nottingham, UK) at 09:00 each morning for
three consecutive days. The number identiﬁed on plain abdom-
inal X-ray taken on the morning of day 4 was multiplied by 1.2
to give whole gut transit time (WGTT) in hours. Regional
transit was assessed from the number of pellets assigned to the
ascending colon, transverse, descending and rectosigmoid as
described by Metcalf and colleagues.19
STATISTICAL METHODS
Efﬁcacy parameters
Baseline values were only available for the screening phase so
the efﬁcacy parameters (except response) were calculated for
each patient as the differences between the endpoints measured
in ondansetron and placebo periods. Frequencies were com-
pared as ratios and treatment effect expressed as percenatges.
Analysis
Analysis was carried out with Stata 12. First, intention-to-treat
analysis (ITT) was carried out with available data. Second, the
data were re-analysed as per protocol (PPA). Baseline variables
were analysed by dropout status with t test, Kruskal–Wallis test
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or χ2 test for symmetrical, skewed or categorical variables
correspondingly.
The continuous efﬁcacy parameters were approximately sym-
metrical and were analysed with linear regression. Preference
and response data were analysed with multinomial logistic
regression. The results were not adjusted for multiple testing.
RESULTS
Participant ﬂow
Of the 125 patients recruited, 120 were randomised as 5 did
not complete the screening phase. The CONSORT diagram
(ﬁgure 2) summarises the ﬂow. There were 47 (77%) patients
with ondansetron/placebo sequence and 51 (88%) patients with
placebo/ondansetron sequence, giving 98 (82%) patients avail-
able for ITT analysis. Nearly twice as many patients dropped
out from the ondansetron/placebo arm compared with placebo/
ondansetron (p=0.110), mostly during the placebo period (risk
ratio for dropping out when starting with ondansetron is 1.9,
95% CI 0.8 to 4.5). Those who dropped out had more bloating
and more frequent need to go to toilet (table 1). Ninety (75%)
patients were available for PPA.
Primary efﬁcacy parameter
The difference in stool form between ondansetron and placebo
was −0.9, 95% CI −1.1 to −0.6, p<0.001, which showed a sig-
niﬁcant improvement when taking ondansetron compared with
placebo. Worse diarrhoea at baseline was associated with
decreased effect of ondansetron (every 1 point baseline average
stool form increase reduced effectiveness by 0.4 points, 95% CI
0.00 to 0.8, p=0.032). For example, people with less severe
diarrhoea (lower quartile: average stool form 4.9) beneﬁted
more from ondansetron (stool form difference −1.0, 95% CI
−1.3 to −0.7, p<0.001) compared with those with more severe
diarrhoea (upper quartile: average stool form 5.9), with stool
form difference −0.7, 95% CI −1.0 to −0.4, p<0.001.
PPA showed average −0.9, 95% CI −1.2 to −0.6 stool form
difference between ondansetron and placebo. One point
increase in baseline stool form was associated with decreased
effect of ondansetron by 0.5 points, 95% CI 0.1 to 0.8,
p=0.017.
One concern about crossover design studies is the possibility
of a carryover effect such that those who received active treat-
ment ﬁrst would have less symptoms at the beginning of the
second treatment period. However the washout period of
Figure 2 Consort diagram showing patient ﬂow with dropouts and protocol violations. CRP, C-reactive protein.
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2 weeks was sufﬁcient for most patients to report their symp-
toms were back to baseline and only 17 (17%) needed longer,
the maximum period being 36 days. They were asked whether
their bowel dysfunction was back to its usual pre-study level and
this was conﬁrmed objectively from their symptom diaries on
visit 5. Average stool consistency in the week prior to starting
the second arm of the trial was slightly improved at 5.2 com-
pared with 5.4 for baseline (p=0.031) but there was no differ-
ence according to whether active was ﬁrst or second (Figure 3).
Furthermore, with respect to either average bloating, urgency or
abdominal pain scores, there was no difference in the last 7 days
of the washout period between those who had active or placebo
ﬁrst, the differences being 0.17 (0.2), 0.01 (0.2) and 0.10 (0.2),
p=0.4, 0.7 and 0.6, respectively. Thus symptoms at the start of
the second period were not affected by the treatment allocation
in the ﬁrst phase (Figure 3). As can be seen, there was very little
placebo response and onset of treatment effect and loss of effect
on discontinuing ondansetron was rapid, occurring within the
ﬁrst week in both cases. The median (IQR) dose was 4 (2–6.5)
mg for responders and 8 (4–20) mg for non-responders for
stool consistency.
Secondary efﬁcacy parameters
Table 2 shows that in the ITT analysis the number of days with
pain and average pain score did not change on ondansetron but
patients experienced signiﬁcantly fewer days with urgency and
bloating. Average urgency scores and average frequency of
defaecation were signiﬁcantly lower compared with placebo,
though the fall in average bloating scores did not achieve statis-
tical signiﬁcance. Baseline characteristics did not correlate with
the above efﬁcacy parameters. The results were similar for PPA.
IBS SSS fell compared with baseline when taking ondansetron
by 83±9.8 points, signiﬁcantly more than the 37±9.7-point fall
on placebo, p=0.001. A fall of 50 points in the IBS SSS is
regarded as clinically signiﬁcant.
Using the FDA criteria, 80% of patients responded with a
reduction in number of days with loose stools while taking
ondansetron compared with 41% on placebo. The FDA cri-
teria for pain were met by 43% on ondansetron and 40% on
placebo and the combined FDA criteria were met by 41% on
ondansetron and 17% on placebo. Preference data were avail-
able only for a subsample of patients (N=94 for ITT and
N=86 for PPA). Table 3 shows the preference distribution.
A signiﬁcantly higher proportion of patients prefer, would con-
tinue with and had adequate relief with ‘ondansetron but not
placebo’ compared with ‘placebo but not ondansetron’ (all
p<0.001).
Gut transit time
Gut transit time (table 4) was available for 87 patients in the
ITT analysis and 81 patients in the PPA. Both showed
Table 1 Baseline characteristics of patients compared with those who dropped out
Available for analysis (N=98) Dropped out (N=22)
p Value (difference between
analysed and dropped out)
Age 41 (12) 40 (12) 0.689
Gender (women), N (%) 74 (75.0) 14 (64.0) 0.303
Stool form 5.4 (0.7) 5.5 (0.7) 0.758
Days with morning rush*, median (IQR) 1 (0–3) 2 (0–6) 0.078
Days with pain, median (IQR) 6 (3–7) 6.5 (5–7) 0.256
Days with urgency, median (IQR) 6.5 (5–7) 7 (6–7) 0.642
Days with bloating, median (IQR) 6 (3–7) 7 (5–7) 0.252
Pain score 1.3 (0.8) 1.5 (0.8) 0.574
Urgency score 1.6 (0.7) 1.6 (0.8) 0.826
Bloating score 1.3 (0.9) 1.7 (0.9) 0.085
Frequency of defaecation per day, median (IQR) 2.6 (1.9–3.7) 3.6 (2.1–6.6) 0.033
Anxiety 9.5 (4.3) 10.4 (5.5) 0.553
Depression, median (IQR) 5 (3–9) 5.5 (1–10) 0.670
Patient Health Questionnaire 15 12 (4.0) 13.3 (5.0) 0.283
IBS severity score 302 (85) 330 (83) 0.324
Patient stress score 17.9 (7.4) 20.3 (8.8) 0.322
IBS QOL 455 (150) 403 (189) 0.102
Means (SDs) are shown if not stated otherwise.
*Defined as more than three bowel movements before midday.
IBS, irritable bowel syndrome; QOL, quality of life.
Figure 3 Time course for stool consistency during the two treatment
periods. Time shown in weeks. Washout period was variable so the
value during the last 7 days is shown as the ﬁrst data point in the
treatment period 2. The graph shows very little placebo effect with
rapid onset of treatment effect on commencing ondansetron and loss
of effect on discontinuing.
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signiﬁcantly longer values for ondansetron compared with
placebo, with differences of 10 h, 95% CI 6 to 14 h, p<0.001.
Patients with IBS-D on placebo showed signiﬁcantly faster
transit, with values of 16 (7 to 29) h compared with 46 (12 to
58) h for healthy controls. Regional transit times are given in
table 4, showing that the most marked difference was in the
faster transit through the left colon and rectosigmoid, something
which ondansetron tended to correct, shifting transit towards
the normal range so that transit times were no longer signiﬁ-
cantly different from controls. We found no difference in this
effect between the three SERT promoter polymorphisms,
though there was a tendency for the sl genotype to be associated
with a greater clinical effect and the WGTT increase was 17.1
(10.6 to 23.7) for the sl genotype compared with 4.9 (−3.0 to
Table 3 Patient preferences and true stool responder data
Ondansetron
No
Placebo
Yes
Ondansetron
Yes
Placebo
No
Ondansetron
No
Placebo
No
Ondansetron
Yes
Placebo
Yes
Risk ratio to prefer ‘ondansetron but not placebo’
compared with ‘placebo but not ondansetron’
ITT (N=94)
Preference, N (%) 15 (16) 70 (74) 9 (10) 0 (0) 4.7 (2.7 to 8.2)
p value <0.001
Continue, N (%) 15 (16) 67 (71) 11 (12) 1 (1) 4.5 (2.6 to 7.8)
p value <0.001
Adequate Relief, N (%) 13 (14) 61 (65) 17 (18) 3 (3) 4.7 (2.6 to 8.5)
p value <0.001
PPA (N=86)
Preference, N (%) 13 (15) 66 (77) 7 (8) 0 (0) 5.1 (2.8 to 9.2)
p value <0.001
Continue, N (%) 14 (16) 64 (74) 7 (8) 1 (1) 4.6 (2.6 to 8.2)
p value <0.001
Adequate Relief, N(%) 11 (13) 58 (67) 14 (16) 3 (3) 5.3 (2.8 to 10.0)
p value <0.001
Response data
ITT (N=98)
True stool responder
Response, N (%) 6 (6) 44 (45) 14 (14) 34 (35) 7.3 (3.1 to 17.2)
p value <0.001
PPA (N=90)
Response, N (%) 5 (6) 43 (48) 11 (12) 31 (34) 8.6 (3.4 to 21.7)
p value <0.001
*Ratios are shown for probability that people would prefer a particular choice compared with the choice ‘Placebo yes but ondansetron no’. For example, it is much more probable
(4.2 times, 95% CI 2.5 to 7.1) that patients prefer ‘Ondansetron but not placebo’ compared with ‘Placebo but not ondansetron’. The same applies to ‘continue’ and ‘adequate relief’
options. Data show that it is more probable (7.3 times, 95% CI 3.1 to 17.2) to respond to ondansetron but not placebo compared with placebo but not ondansetron.
Table 2 Ondansetron effect on secondary outcomes
ITT analysis (N=98) PPA (N=90)
Treatment effect (95% CI) p Value Treatment effect (95% CI) p Value
Days per week with pain −0.3 (−0.7 to 0.1) 0.203 −0.3 (−0.7 to 0.2) 0.227
Days per week with urgency −1.1 (−1.5 to −0.6) <0.001 −1.1 (−1.6 to −0.7) <0.001
Days per week with bloating −0.7 (−1.1 to −0.3) 0.002 −0.7 (−1.1 to −0.3) 0.002
Pain score (0–3)
None (0), mild (1), moderate (2) or severe (3)
−0.10 (−0.22 to 0.03) 0.119 −0.10 (−0.23 to 0.02) 0.103
Urgency score(0–3)
None (0), mild (1), moderate (2) or severe (3)
−0.32 (−0.45 to −0.18) <0.001 −0.33 (−0.47 to −0.19) <0.001
Bloating score(0–3)
None (0), mild (1), moderate (2) or severe (3)
−0.13 (−0.27 to 0.01) 0.070 −0.12 (−0.26 to 0.02) 0.103
Stool frequency reduction, % 11 (4 to 18) 0.001 11 (4 to 18) 0.002
Whole gut transit time increase*, h 10 (6 to 14) <0.001 10 (6 to 14) <0.001
Right colon transit time increase, h 2 (0 to 4) 0.064 2 (0 to 4) 0.082
Left colon transit time increase, h 6 (3 to 8) <0.001 5 (3 to 8) <0.001
Differences between ondansetron and placebo are presented.
*Numbers of patients available for analysis are 87/98 (89%) for ITT and 81/90 (90%) for PPA analysis. Lower numbers reflect patients who failed to take their markers or attend for the
final X-ray.
ITT, intention-to-treat; PPA, per protocol analysis.
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12.8) for ll, ANOVA, p=0.07 (see online supplementary appen-
dix 1).
Adverse events
The only frequently occurring side effect was constipation,
which occurred in 9%10 on ondansetron and 2%2 on placebo.
All responded to dose reduction and only two decided to leave
the trial at that point. Other less frequent side effects included
headache (2 ondansetron, 2 placebo), rectal bleeding (2 ondan-
setron, 2 placebo, none of which were found to be due to
ischaemic colitis), backache (1 ondansetron, 1 placebo) and
abdominal pain (2 ondansetron, 1 placebo).
DISCUSSION
Patients with IBS-D suffer markedly from loose and frequent
stools, and particularly from the associated urgency and fear of
incontinence which generates panic and anxiety. This, therefore
represents an important unmet need. The abnormalities of sero-
tonin metabolism which have been demonstrated in IBS-D make
5-HT3 antagonists a logical treatment. Post-infective IBS, a
subtype of IBS-D with very similar clinical features,20 has been
shown to be associated with increased 5HT-containing enter-
oendocrine cells,21–23 and also increased postprandial 5-HT
release.24 Further studies have also shown reduced mRNA for
SERT in IBS-D duodenal25 and colonic biopsies23 25which, in
keeping with animal studies of post inﬂammatory bowel dys-
function,26 was correlated with mucosal immune response.
Our study showed patients with IBS-D have a clear preference
for ondansetron compared with placebo, even though it did not
alter the number of days with pain, suggesting that for these
patients it was urgency and loose stools which were the most
troublesome symptoms. It is of interest that animal studies have
shown that alosetron, a 5-HT3RA shown to be effective in
IBS-D, inhibits spinal pathways mediating the response to
painful colonic distension.27 We have also shown in a rat model
of postinfective visceral hypersensitivity that ondansetron
reduces afferent ﬁring induced by colonic distension,26 suggest-
ing that ondansetron might have reduced pain if we had used
higher doses. However, this would undoubtedly have produced
more constipation which our patients were keen to avoid.
Although only 41% met FDA criteria for responder to both
pain and consistency, 67% reported adequate relief of symp-
toms, suggesting that when urgency is the main problem ondan-
setron will be effective but less so when pain is the main
complaint. It should be noted that dyspepsia is a common
comorbidity with IBS and earlier studies suggest beneﬁt to
heartburn and postprandial pain.9 Therefore some of the global
beneﬁt may have been from improvement in dyspepsia, though
we did not assess this in the current study. Future studies should
probably include a dyspepsia assessment.
Our variable dosing regime mirrored clinical practice and we
feel gives a better idea of how the drug will perform in clinical
practice. It undoubtedly improved response rate and had we
chosen a ﬁxed dose many patients would have developed consti-
pation and probably dropped out or had worsening symptoms.
As expected, the median number of tablets per day was much
lower for ondansetron than placebo, median (IQR) 1 (0.5–1.4)
and 2 (1–5), respectively. However, dose titration does compli-
cate analysis since only the stool diaries in the last 2 weeks are
truly informative of the response, meaning that we cannot
impute data to allow for incomplete diaries, which would be
normal practice. These incomplete data led to only 98 subjects
being analysed.
Our evaluation time of just 2 weeks was short but in patients
with diarrhoea and rapid transit, drug effects tend to be rapid
and quickly reversible, for example with loperamide. We found
that most subjects returned to their previous bowel habit within
the 2-week washout and only 17 patients required longer.
Our patients were moderately affected by bowel disturbance
and psychological comorbidity similar to other recent trials of
IBS-D treatment,28 so we expect our ﬁndings to be generalisable
to the general IBS population with symptoms severe enough to
warrant referral to secondary care.
Regrettably alosetron, a 5-HT3RA for which there is substan-
tial evidence of beneﬁt,29 was withdrawn from widespread use
because of an unacceptable incidence of severe constipation
(around 25%) and a much lower incidence (0.7 per 1000
patient-years30) of unexplained ischaemic colitis. Our trial
shows that ondansetron can achieve useful results with a low
incidence of side effects. While our small study cannot prove
safety, the fact that the drug has been used widely for over
25 years without a single report of ischaemic colitis suggests
that this side effect will be rare. Constipation occurred in just
9% and rapidly resolved on dose reduction, giving a discontinu-
ation rate due to constipation of just 2%. Our constipation rate
is lower than the 18–29.6% and 10–19.3% respectively
reported in the meta-analysis of alosetron 2 mg and cilansetron
6 mg daily,29 while ramosetron 5 μg was associated with a com-
parable rate of 7.4%.31 Our low rate undoubtedly reﬂects the
use of dose titration, to avoid constipation, with many patients
only requiring 4 mg daily or on alternate days. This mirrors
what would happen in clinical practice. The high incidence of
constipation with alosetron is dose related and 0.5 mg daily is
associated with a much reduced incidence of constipation ( just
9%) with relief of symptoms in 50.8% of patients compared
with 30.7% in placebo.32 Unfortunately ischaemic colitis
remains a concern even at 0.5mg daily despite careful monitor-
ing, with an incidence of 2 per 1000 with alosetron33 and it
seems unlikely that alosetron will ever be marketed worldwide.
Ondansetron’s potency in blocking the 5-HT3 receptor is 3–10
times lower than alosetron,34 which may explain the low inci-
dence of side effects in our study. Ramosetron is another
5-HT3RA, proven effective in IBS-D,35 but unfortunately only
marketed in Japan. It has an afﬁnity for the 5-HT3 receptor
Table 4 Whole gut and regional transit times (median (IQR))
Whole gut transit time Right colon Left colon Rectosigmoid
Healthy controls N=19 46 (12–58) 13 (5–18) 12 (3–24) 7 (4–15)
Patients with IBS-D on placebo 16 (7–29)* 6 (2–12) 2.5 (0–7)*** 4 (1–9)***
Patients with IBS-D on ondansetron 24 (15–47) 7 (3–16) 6 (0–17.25) 7 (2–13)
P for difference on ondansetron NS <0.05 <0.05
*p<0.05, ***p<0.001 versus healthy volunteers.
IBS-D, irritable bowel syndrome with diarrhoea.
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three times that of alosetron36 but is given at a very low dose of
5 μg, equivalent to 0.015 mg alosetron, again suggesting that
lower doses of 5-HT3RAs might well be the best strategy in
treating IBS-D.
Previous authors have reported that individuals with the het-
erozygote sl genotype responded less well to alosetron as
assessed by the change in colonic transit,10 a ﬁnding which does
not seem true for ondansetron (see online supplementary
appendix).
The strongest effects were on transit, stool consistency and
urgency, which are important since urgency is one of the stron-
gest predictors of reduced quality of life37 and as others have
reported, response to 5-HT3RAs also correlates with improve-
ment in quality of life.38
Unlike the larger alosetron trials we did not ﬁnd a signiﬁcant
improvement in abdominal pain versus placebo, with only 41%
of individuals meeting FDA dual criteria for being ‘responders’
for pain and stool consistency, a value not signiﬁcantly different
from 17% on placebo. However, 67% of our patients reported
‘adequate relief ’ from their symptoms with ondansetron but not
placebo, compared with 14% with placebo but not ondansetron.
Furthermore, the IBS SSS score, an overall IBS severity score,
fell signiﬁcantly compared with placebo. The largest numerical
effect we found was the reduction in days with urgency, which
is known to be one of the most bothersome symptoms in
IBS-D1 and a very important driver of impairment of quality of
life.39 It is also rated by patients as the most important attribute
of a successful treatment for IBS-D.40
We found that those most severely affected were more likely
to drop out, less likely to respond and showed a smaller reduc-
tion in stool consistency, indicating that the efﬁcacy for treating
severe diarrhoea is limited and the best response will be in those
with mild to moderate symptoms who represent the majority of
patients seen in primary care. However, given its safety, low side
effect proﬁle and rapid onset of effect within 1 week in most
cases, a trial of treatment would seem reasonable in most cases
of IBS-D. Whether it would help patients with functional diar-
rhoea remains to be determined.
Ondansetron is a generic drug, available worldwide at a low
price, with a very long experience of safe usage, which our
study suggests would beneﬁt patients with IBS-D troubled
mainly by urgency and loose stools.
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